Basilea announces CHF 75 million senior secured loan

0

Ad hoc announcement pursuant to Art. 53LR

Basel/Allschwil, Switzerland, September 07, 2022

Basilea Pharmaceutica Ltd (SIX:BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with serious bacterial and fungal infections, today announced that it has entered into a senior secured loan agreement with funds managed by Athyrium Capital Management, LP (“Athyrium”). The senior secured loan of CHF 75 million will be used by Basilea for the repayment of its convertible bonds (ISIN CH0305398148), which mature in December 2022 for an outstanding nominal amount of approximately CHF 117 million.

Adesh Kaul, Chief Financial Officer of Basilea, said, “We are pleased to have secured this non-dilutive refinancing of our outstanding 2022 convertible bonds. The transaction allows us to achieve our objectives of reducing our debt level and avoiding dilution for our shareholders. Based on our strong financial position and growth prospects, we will be able to pay the remainder of the outstanding 2022 convertible bonds with available cash and, in addition, we intend to repay the secured loan. senior CHF 75 million within two years from cash. the flows that should be generated by our growing commercial activity.

Laurent D. Hermouet, Partner at Athyrium, added: “We are delighted to work with Basilea to support its anti-infectious strategy. Basilea has demonstrated strong capabilities in the development, partnership and commercialization of anti-infectives and we look forward to the continued advancement of its candidates.

The senior secured loan has a term of two years and repayment is expected to start from the first quarter of 2023 on a quarterly basis. Interest payments, excluding fees, are expected to average approximately CHF 1.25 million per quarter over the term. The transaction is subject to customary closing conditions.

The transaction has no impact on Basilea’s financial forecast for 2022.

About Athyrium Capital Management

Athyrium is a specialist asset management firm established in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium advises funds with over $4.6 billion in committed capital. The Athyrium team has extensive experience investing across a wide range of asset classes, including public equities, private equities, fixed income, royalty and other structured securities. Athyrium invests in all healthcare verticals, including biopharmaceuticals, medical devices and products, healthcare-oriented services and healthcare information technology. The team partners with management teams to implement creative financing solutions that meet companies’ capital needs. For more information, visit www.athyrium.com.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative medicines to meet the needs of patients with bacterial and fungal infections. We successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally, we have several preclinical anti-infective actives in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “plan”, “project”, “may”, “could”, “could”, “will”. or similar expressions regarding Basilea Pharmaceutica Ltd and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd to be materially different from any future results, performance or achievements expressed or implied by these statements. research statements. Basilea Pharmaceutica Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For more information, please contact:

This ad hoc announcement can be downloaded from www.basilea.com.

Share.

Comments are closed.